Company Name: Lucky Core Industries Ltd
Ticker: LCI
Reporting period: Year ended June 30, 2026
Reporting basis: Audited consolidated results for Lucky Core Industries Limited and its subsidiary Lucky Core PowerGen Limited are the primary basis of this analysis. Standalone figures are identified separately. Amounts are in Pakistani rupees; financial-statement figures are in PKR thousands unless stated otherwise.
Verdict
Lucky Core Industries closed FY2026 with a resilient fourth-quarter bottom line but weaker underlying industrial earnings. Consolidated turnover fell 5.5%, gross profit declined 10.4% and operating profit fell 18.2%. Pharmaceuticals and Animal Health had been growing through March, but Polyester and Soda Ash were under pressure from low-cost imports, weak demand and energy costs. Full-year profit after tax declined 17.1% to PKR 9.75 billion. More importantly, net operating cash flow fell 68.2% as inventory and receivables rose and supplier balances declined. Implied fourth-quarter profit increased despite lower operating profit because other income and associate earnings improved; that makes the quality and repeatability of the late-year recovery the key issue to monitor. The official FY2026 results filing contains the audited consolidated and standalone statements.
AlphaGen model readings
The following four readings are AlphaGen model outputs, not company-reported financial figures:
- Alpha QoQ Score: 78.33
- TTM Performance Score: 14.25
- 3Y Business Perf Score: 42.43
- Sector Leadership Score: 36.2154
Reporting basis and announcement
The board approved the annual audited financial statements on August 3, 2026. Consolidated results include Lucky Core PowerGen Limited, while standalone results represent the listed parent. The difference is small at the top and bottom lines: consolidated turnover was PKR 113.38 billion and profit after tax was PKR 9.75 billion; standalone turnover was PKR 113.21 billion and profit after tax was PKR 9.69 billion. This article uses consolidated figures for group performance and standalone EPS only where explicitly noted. LCI’s PSX filing confirms the date, scope and two reporting bases.
LCI operates five business verticals spanning Soda Ash, Polyester, Pharmaceuticals, Animal Health, and Chemicals & Agri Sciences. The latest detailed segment commentary covers the nine months to March 2026; the August results filing provides full-year statements but not a full-year segment table. Segment explanations below are therefore dated and clearly separated from the audited full-year totals. The company describes its operating portfolio on its official website.
Full-year comparison
Revenue and gross profitability
- Net turnover: PKR 113.38 billion in FY2026 versus PKR 119.94 billion in FY2025, down 5.5%. Lower revenue means the portfolio did not fully offset industrial-volume and pricing pressure.
- Gross profit: PKR 24.59 billion versus PKR 27.45 billion, down 10.4%. Gross margin narrowed to 21.7% from 22.9%, showing that cost of sales declined more slowly than turnover.
- Operating profit: PKR 14.74 billion versus PKR 18.03 billion, down 18.2%. Operating margin fell to 13.0% from 15.0%, as administration costs rose and the lower gross profit flowed through.
All three comparisons come from the audited consolidated profit-and-loss statement. Selling and distribution expense declined 3.4% to PKR 6.93 billion, but administration and general expense increased 29.6% to PKR 2.91 billion. The expense mix therefore did not provide enough relief to protect operating profit. See Annexure A1 of the official FY2026 results.
Below operating profit
- Finance costs: PKR 2.49 billion versus PKR 2.21 billion, up 12.7%. Higher short-term financing reduced the benefit of lower policy rates.
- Other income: PKR 3.57 billion versus PKR 3.44 billion, up 3.6%. This provided meaningful support outside core operations.
- Share of profit from associate: PKR 289.8 million versus PKR 19.3 million. The increase was material relative to the associate contribution, though still modest beside group operating profit.
- Profit before final taxes and income tax: PKR 15.21 billion versus PKR 18.63 billion, down 18.4%.
- Profit after tax: PKR 9.75 billion versus PKR 11.76 billion, down 17.1%. Net margin declined to 8.6% from 9.8%.
- EPS attributable to owners: PKR 21.11 versus PKR 25.46, down 17.1%. Standalone EPS was PKR 20.99 versus PKR 25.20.
The current and deferred income-tax charge totalled PKR 6.45 billion. Measured against profit before income tax, the effective burden was about 42.4%, compared with approximately 36.9% in FY2025. Tax therefore remained an additional drag even though the absolute charge declined. The audited consolidated statement separates final taxes, current tax and deferred tax.
What happened in the fourth quarter
Subtracting the official nine-month consolidated statements from the audited full year gives an implied April-to-June quarter. This is an AlphaGen calculation from company-reported figures, not a separately published quarterly statement. Implied fourth-quarter turnover was about PKR 27.99 billion, broadly flat against PKR 27.89 billion in the comparable quarter. Gross profit declined about 4.8% to PKR 6.17 billion, and operating profit fell about 18.2% to PKR 3.55 billion. The nine-month consolidated statement provides the March base for the calculation.
Yet implied fourth-quarter profit after tax rose about 16.9% to PKR 3.25 billion. The bridge is below operating profit: implied other income was roughly PKR 1.93 billion versus PKR 0.63 billion, and the associate contributed about PKR 114.7 million versus a small loss in the comparable quarter. Finance cost, meanwhile, rose sharply. Economically, the quarter shows a better reported bottom line without a corresponding recovery in core operating profit. Readers should therefore test whether other income is recurring before treating the fourth-quarter profit improvement as a new earnings run-rate.
Segment and product performance
LCI’s detailed nine-month review showed a divided portfolio. Pharmaceuticals turnover rose 10% to PKR 17.11 billion and operating profit increased 18% to PKR 4.05 billion. Management attributed this to portfolio breadth, cost optimisation and operating efficiencies. Animal Health turnover rose 19% to PKR 5.33 billion and operating profit increased 17% to PKR 914 million, supported by locally manufactured medicines and veterinary demand. These are management explanations for the nine months ended March 31, 2026, not full-year segment figures. The official March 2026 report provides the segment results and management commentary.
The industrial businesses were weaker. Polyester turnover fell 20% to PKR 25.49 billion and operating profit dropped 87% to PKR 215 million. Management cited lower sales volumes, margin pressure, low-cost imports and higher energy costs. Soda Ash turnover declined 8% to PKR 27.78 billion and operating profit fell 25% to PKR 4.64 billion, with weaker domestic demand, tariff reductions and low-priced imports weighing on performance. Chemicals & Agri Sciences turnover fell 4% to PKR 9.77 billion and operating profit declined 11% to PKR 1.33 billion; flooding and subdued agricultural-input demand hurt the Agri Sciences portion. LCI’s nine-month business review details these movements and stated causes.
The mix matters economically. Healthcare growth carries product and regulatory risk but provided earnings diversification when commodity-linked industrial businesses were squeezed. Polyester and Soda Ash are exposed to imported-product pricing, feedstock, energy, freight, tariffs and downstream demand. A durable recovery needs either better industrial volumes and spreads or enough healthcare growth to outweigh those cyclical pressures.
Balance sheet and working capital
Consolidated total assets increased 6.6% to PKR 111.22 billion, while equity rose 8.1% to PKR 59.44 billion. Property, plant and equipment was broadly stable at PKR 38.62 billion. The more consequential changes were in working capital: stock-in-trade rose 16.5% to PKR 19.97 billion and trade debts increased 23.0% to PKR 6.23 billion, while trade and other payables fell 22.3% to PKR 12.22 billion. The audited consolidated balance sheet reports the June 2026 and June 2025 positions.
Those movements consume cash because more money is tied up in inventory and customer credit while less financing is provided by suppliers. Short-term financing increased 60.2% to PKR 16.83 billion. Long-term and current portions of loans together were about PKR 10.51 billion, slightly below the prior year, so the funding mix shifted toward shorter-duration borrowing. That helps explain why finance cost increased even as benchmark interest rates had eased during much of the year.
Cash flow and capital allocation
Cash generated from operations fell 47.7% to PKR 14.36 billion. After interest, taxes and employee-benefit payments, net operating cash flow dropped 68.2% to PKR 5.79 billion from PKR 18.19 billion. Capital expenditure was PKR 4.31 billion, down from PKR 9.10 billion, leaving only a narrow operating-cash surplus after capital spending before dividends and financing flows. The consolidated cash-flow statement provides the audited cash movements.
LCI paid PKR 5.27 billion of dividends during FY2026. The board recommended a final cash dividend of PKR 5.25 per PKR 2 share, on top of an interim PKR 5.25 per share already paid. The total FY2026 distribution is therefore PKR 10.50 per share, subject to shareholder approval of the final dividend. Against consolidated EPS of PKR 21.11, that represents roughly half of reported earnings. The policy returns cash to shareholders, but weaker operating cash conversion makes inventory, receivables and borrowing important constraints on future distributions. The August 3 results announcement states the final and interim dividend terms.
Recurring and non-recurring drivers
The decline in turnover, gross margin and operating profit reflects the recurring economics of the operating businesses. Finance cost also recurs while borrowing remains elevated. By contrast, associate income can vary with another company’s results, and other income may include investment returns or items that do not scale with product sales. FY2025 also contained a PKR 292.6 million bargain-purchase gain that did not recur in FY2026. These distinctions explain why core operating profit is a cleaner indicator than profit after tax for judging the industrial recovery.
Risks and what to monitor next
- Industrial demand and imports: watch Polyester and Soda Ash volumes, pricing and operating profit, especially after tariff changes and import competition.
- Healthcare execution: monitor whether Pharmaceuticals and Animal Health can sustain growth after product expansion and the March 2026 commissioning of the veterinary medicine facility.
- Gross and operating margins: recovery requires more than stable sales; cost absorption and product mix must improve.
- Working capital: inventory, receivable days and supplier balances will determine whether earnings convert into cash.
- Funding: track short-term financing and finance cost after the FY2026 increase.
- Other income and associate contribution: separate recurring operating earnings from non-core support, particularly when assessing the implied fourth-quarter improvement.
- Dividend coverage: compare future payouts with free cash generation, not EPS alone.
LCI’s diversification remains a structural strength, but FY2026 demonstrates that diversification does not prevent earnings compression when major industrial segments weaken simultaneously. The favourable environment would combine stronger construction and textile demand, disciplined imports, stable energy and feedstock costs, healthcare growth and faster cash collection. The adverse environment is the reverse: low-priced imports, weak downstream demand, rising energy or petrochemical costs, prolonged inventory holding and greater reliance on short-term borrowing. The PSX company record confirms LCI’s activities and current filing history.